Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $5.07 Million - $5.67 Million
-87,585 Reduced 85.82%
14,472 $839,000
Q2 2023

Aug 11, 2023

SELL
$63.71 - $70.74 $4.4 Million - $4.88 Million
-69,009 Reduced 40.34%
102,057 $6.53 Million
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $636,072 - $721,450
-9,680 Reduced 5.36%
171,066 $11.9 Million
Q4 2022

Feb 13, 2023

BUY
$68.48 - $81.09 $285,082 - $337,577
4,163 Added 2.36%
180,746 $13 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $2,194 - $1.3 Million
-16,879 Reduced 8.72%
176,583 $12.6 Million
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $706,737 - $778,365
-9,732 Reduced 4.79%
193,462 $14.9 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $486,306 - $583,125
7,910 Added 4.05%
203,194 $14.8 Million
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $526,861 - $614,196
9,824 Added 5.3%
195,284 $12.2 Million
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $8.6 Million - $10.1 Million
145,335 Added 362.21%
185,460 $11 Million
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $120,972 - $131,738
1,954 Added 5.12%
40,125 $2.68 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $2.27 Million - $2.55 Million
38,171 New
38,171 $2.41 Million
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $262,523 - $340,430
-5,384 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $309,947 - $349,596
-5,616 Reduced 51.05%
5,384 $334,000
Q2 2018

Aug 14, 2018

SELL
$50.53 - $62.98 $2.26 Million - $2.82 Million
-44,749 Reduced 80.27%
11,000 $609,000
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $768,893 - $885,151
12,832 Added 29.9%
55,749 $3.53 Million
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $2.57 Million - $2.8 Million
42,917
42,917 $2.63 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Stansberry Asset Management, LLC Portfolio

Follow Stansberry Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stansberry Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stansberry Asset Management, LLC with notifications on news.